Literature DB >> 18188709

Liver embolizations in oncology: a review. Part I. Arterial (chemo)embolizations.

Peter Gunvén1.   

Abstract

Arterial embolization of the liver often temporarily retards the growth of liver tumors which are mainly nourished arterially. The use of degradable agents avoids collateral formation which would prohibit repeat procedures and permit tumor regrowth. The effect of embolizations is largest in small hypervascular lesions, e.g., many hepatocellular or neuroendocrine cancers. Toxic chemicals can be added, chemoembolization, with unproven effects on responses and survival rates. Institutional differences in indications and procedures make evaluation of embolizations difficult. However, intermediate-term survival increases in selected cases of unresectable hepatocellular cancers and hormonal symptoms from neuroendocrine tumors often improve. Scant experience supports embolization for anti-tumoral effects in some pediatric tumors, to control bleeding from ruptured tumors, for symptomatic hemangiomas, and for downstaging of hepatocellular cancers before transplantation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18188709     DOI: 10.1007/s12032-007-0039-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  123 in total

Review 1.  Chemoembolization of hepatic neoplasms: safety, complications, and when to worry.

Authors:  J Gates; G G Hartnell; K E Stuart; M E Clouse
Journal:  Radiographics       Date:  1999 Mar-Apr       Impact factor: 5.333

Review 2.  Cerebral lipiodol embolism during transcatheter arterial chemoembolization.

Authors:  K M Yoo; B G Yoo; K S Kim; S U Lee; B H Han
Journal:  Neurology       Date:  2004-07-13       Impact factor: 9.910

3.  Combined peripheral and central chemoembolization of liver tumors. Experience with lipiodol-doxorubicin and gelatin sponge (L-TAE).

Authors:  Y Shimamura; P Gunvèn; Y Takenaka; H Shimizu; Y Shima; H Akimoto; K Arima; A Takahashi; T Kitaya; T Matsuyama
Journal:  Cancer       Date:  1988-01-15       Impact factor: 6.860

Review 4.  Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS).

Authors:  U Plöckinger; G Rindi; R Arnold; B Eriksson; E P Krenning; W W de Herder; A Goede; M Caplin; K Oberg; J C Reubi; O Nilsson; G Delle Fave; P Ruszniewski; H Ahlman; B Wiedenmann
Journal:  Neuroendocrinology       Date:  2005-04-18       Impact factor: 4.914

5.  Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver.

Authors:  Huda S Salman; Jacov Cynamon; Marci Jagust; Curtis Bakal; Alla Rozenblit; Ron Kaleya; Abdissa Negassa; Scott Wadler
Journal:  Clin Colorectal Cancer       Date:  2002-11       Impact factor: 4.481

6.  Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma.

Authors:  Thomas Decaens; Françoise Roudot-Thoraval; Solange Bresson-Hadni; Carole Meyer; Jean Gugenheim; Francois Durand; Pierre-Henri Bernard; Olivier Boillot; Karim Boudjema; Yvon Calmus; Jean Hardwigsen; Christian Ducerf; Georges Philippe Pageaux; Sebastien Dharancy; Olivier Chazouilleres; Daniel Dhumeaux; Daniel Cherqui; Christophe Duvoux
Journal:  Liver Transpl       Date:  2005-07       Impact factor: 5.799

7.  Continuous versus intermittent portal triad clamping for liver resection: a controlled study.

Authors:  J Belghiti; R Noun; R Malafosse; P Jagot; A Sauvanet; F Pierangeli; J Marty; O Farges
Journal:  Ann Surg       Date:  1999-03       Impact factor: 12.969

Review 8.  Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.

Authors:  Calogero Cammà; Filippo Schepis; Ambrogio Orlando; Maddalena Albanese; Lillian Shahied; Franco Trevisani; Pietro Andreone; Antonio Craxì; Mario Cottone
Journal:  Radiology       Date:  2002-07       Impact factor: 11.105

9.  Improvement of metastatic endocrine tumors of the pancreas by hepatic artery chemoembolization.

Authors:  M Nesović; J Cirić; S Radojković; M Zarković; M Durović
Journal:  J Endocrinol Invest       Date:  1992 Jul-Aug       Impact factor: 4.256

10.  Comparison of long-term effects between intra-arterially delivered ethanol and Gelfoam for the treatment of severe arterioportal shunt in patients with hepatocellular carcinoma.

Authors:  Ming-Sheng Huang; Qu Lin; Zai-Bo Jiang; Kang-Shun Zhu; Shou-Hai Guan; Zheng-Ran Li; Hong Shan
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

View more
  5 in total

1.  Clinical trial of cisplatin-conjugated gelatin microspheres for patients with hepatocellular carcinoma.

Authors:  Tetsuya Toyama; Norihisa Nitta; Shinichi Ohta; Toyohiko Tanaka; Yukihiro Nagatani; Masashi Takahashi; Kiyoshi Murata; Hisanori Shiomi; Shigeyuki Naka; Yoshimasa Kurumi; Tohru Tani; Yasuhiko Tabata
Journal:  Jpn J Radiol       Date:  2011-12-17       Impact factor: 2.374

2.  Liver abscess as a complication of hepatic transarterial chemoembolization: a case report, literature review, and clinical recommendations.

Authors:  Ari M Vanderwalde; Howard Marx; Lucille Leong
Journal:  Gastrointest Cancer Res       Date:  2009-11

Review 3.  Percutaneous treatment of thoracic duct injuries.

Authors:  Francesca Marcon; Katayun Irani; Theresa Aquino; John K Saunders; Thomas H Gouge; Marcovalerio Melis
Journal:  Surg Endosc       Date:  2011-05-17       Impact factor: 4.584

4.  A multidisciplinary approach to the management of hepatocellular carcinoma.

Authors:  Robert G Gish; Jorge A Marrero; Al B Benson
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-03

Review 5.  Magnetic Nanomaterials for Arterial Embolization and Hyperthermia of Parenchymal Organs Tumors: A Review.

Authors:  Natalia E Kazantseva; Ilona S Smolkova; Vladimir Babayan; Jarmila Vilčáková; Petr Smolka; Petr Saha
Journal:  Nanomaterials (Basel)       Date:  2021-12-15       Impact factor: 5.076

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.